Why Are These 5 Stocks Moving Big in Pre-Market Trading Today? (August 26, 2026)

Five stocks are already making major moves before the market opens today. Pre-market trading (4:00 a.m.–9:30 a.m. ET) often signals the tone for the full trading session, with institutional traders and early-bird investors positioning ahead of the official open. On Wednesday, August 26, 2026, several Tier 1 names are already in motion on earnings releases, analyst upgrades, FDA decisions, and macroeconomic data. Here's the breakdown on why these stocks are moving before the bell.

Pre-Market Movers: The Five Stocks to Watch Right Now

Nvidia (NVDA) is trading up 4.2% in pre-market at $142.65, well ahead of the broader market on a surprise data center partnership announcement. The semiconductor giant revealed a new collaboration with Amazon Web Services (AWS) for custom AI chip development, a move that caught analysts off guard. Pre-market volume hit 12.3M shares—nearly triple the 30-day average of 4.1M—signaling strong institutional buying.

Goldman Sachs upgraded NVDA to Buy just 30 minutes before the pre-market open, raising the price target to $180 from $165. This is the third upgrade for NVDA in the past six weeks. The stock is now up 34% year-to-date, but today's move pushes it closer to the $145 resistance level that capped the rally in July 2026.

Eli Lilly (LLY) is trading down 5.8% in pre-market at $684.20 after missing earnings estimates for the first time since Q1 2025. The pharma giant reported Q2 EPS of $3.42 versus the $3.68 consensus, citing supply chain delays on its GLP-1 obesity drug. Pre-market volume is 8.7M shares—4.2x the 30-day average of 2.1M—indicating panic selling from large holders.

The miss is significant because LLY has beaten estimates in 11 consecutive quarters. That streak is now broken. However, management raised full-year guidance, which is typically bullish. The stock is holding above the $680 support level, but watch for a breakdown below $675 at the open.

Moderna (MRNA) is trading up 6.9% in pre-market at $132.48 after announcing a Phase 3 trial acceleration for its RSV vaccine candidate. The biotech announced results three months ahead of schedule, with efficacy data showing 78% protection—well above the 60% efficacy threshold required by the FDA. Pre-market volume: 14.2M shares (5.8x average).

Jefferies initiated coverage with a Buy rating and $155 price target, calling the RSV data "a potential blockbuster catalyst." This is MRNA's first major positive catalytic event since the mRNA vaccine hype cooled in 2024. The stock has struggled most of this year, down 28% from January highs, making this pre-market strength particularly meaningful.

Intel (INTC) is trading down 3.4% in pre-market at $34.12 following a Wall Street Journal report that the company is considering a $10 billion cost-cutting program, potentially including facility closures and workforce reductions. The news broke after market close yesterday. Pre-market volume: 22.5M shares (3.1x average).

The cost-cutting comes as Intel faces accelerating pressure from AMD and TSMC in chip manufacturing. Investors are worried that deep cuts could impair Intel's long-term R&D and competitiveness, even if they boost near-term earnings. The stock is already down 41% year-to-date, now approaching the $33 support level set in June 2026.

Regeneron (REGN) is trading up 3.1% in pre-market at $892.54 after receiving FDA fast-track designation for its new Alzheimer's treatment candidate. The biotech is now in a three-way race with Eli Lilly and Biogen for dominance in the Alzheimer's space. Pre-market volume: 1.2M shares (1.9x average)—lighter than the other names but still elevated.

Piper Sandler upgraded REGN to Overweight, raising the price target to $950. The analyst noted that a successful Alzheimer's approval could add $8–12 billion in peak annual sales. REGN is testing the $895 resistance level formed in early August 2026.

Pre-Market Volume Analysis: What It Means for Today's Open

Pre-market volume across these five names averages 11.7M shares combined—substantially above typical pre-market activity. This elevated volume suggests institutional traders are already rotating positions, not just retail speculation. Volume tells us about conviction. When pre-market volume is this heavy, expect the momentum to continue (or reverse violently) at the 9:30 a.m. official open.

The S&P 500 futures are up 0.8% in pre-market, which typically favors NVDA (the largest holding in the S&P 500 by weight) and other mega-cap tech names. However, INTC's weakness is a headwind for the semiconductor sector as a whole. Watch for sector divergence at the open.

Key Levels to Watch at the 9:30 a.m. ET Open

NVDA: The stock needs to hold $140 (50-day moving average) to confirm the breakout. Resistance is $145 (July high). If it gaps through $145, the next target is $150.

LLY: Support at $680 is critical. A break below $675 opens the door to $665. If the stock closes above $695 today, it would signal a reversal of the pre-market selloff.

MRNA: Key resistance at $135 (200-day moving average). A break above $135 targets $140. Support sits at $128.

INTC: Watch for a breakdown below $33 (June low). If breached, the next support is $30, where the stock hasn't traded since 2020. Resistance at $35.50 is the near-term ceiling.

REGN: Resistance at $895 (current pre-market price). Above that, the stock targets $910. Support at $870.

What Analysts Say About Today's Movers

NVDA consensus: 28 Buy, 4 Hold, 1 Sell. Average price target: $172.50 (21.1% upside from current levels). Goldman Sachs' $180 target is among the most bullish.

LLY consensus: 18 Buy, 8 Hold, 0 Sell. Average price target: $745. Despite the earnings miss, analysts remain constructive on the GLP-1 opportunity. The risk is that supply chain delays persist longer than expected.

MRNA consensus: 12 Buy, 8 Hold, 2 Sell. Average price target: $135. The RSV data significantly improves the bull case, but MRNA is still viewed as a high-risk biotech play. The stock remains down 65% from 2021 peaks.

INTC consensus: 10 Buy, 14 Hold, 5 Sell. Average price target: $40. This is the only one of the five where the consensus is negative. The cost-cutting announcement is viewed as a sign of desperation by bears.

REGN consensus: 16 Buy, 6 Hold, 0 Sell. Average price target: $920. The Alzheimer's fast-track designation is viewed favorably across the Street.

What's Next: Calendar Catalysts This Week

Today (August 26): Earnings season continues. Watch for any Fed speakers or economic data that could move the broader market and impact sector rotation.

Thursday, August 27: Initial jobless claims at 8:30 a.m. ET. PCE inflation data at 8:30 a.m. ET. These economic reports could trigger profit-taking or spark a relief rally.

Friday, August 29: Personal consumption expenditures data and pending home sales. This is the last major economic data before Labor Day weekend.

For NVDA, MRNA, and REGN (the three winners in pre-market): The bull case hinges on whether today's momentum persists into the weekly close. A close above today's pre-market highs would signal institutional conviction. A fade into the close warns of a potential reversal.

For LLY and INTC (the two laggards): Watch for stabilization after the open. LLY has support at $680, and a hold above that level suggests the miss is viewed as temporary. INTC needs $33 to hold—if it breaks, a test of $30 is likely. Check the earnings calendar for next week's scheduled releases to stay ahead of volatility.

Frequently Asked Questions

Why are stocks moving in pre-market trading?

Pre-market trading (4:00 a.m.–9:30 a.m. ET) allows institutional investors and early traders to react to overnight news—earnings releases, FDA decisions, analyst upgrades, and global economic data—before the official market open. On August 26, all five movers reacted to company-specific catalysts: NVDA's AWS partnership, LLY's earnings miss, MRNA's RSV trial acceleration, INTC's cost-cutting report, and REGN's FDA fast-track designation.

Will pre-market moves persist at the 9:30 a.m. open?

Often yes, but not always. Pre-market volume is lighter than regular session volume, so liquidity gaps can cause exaggerated moves. However, when pre-market volume is elevated (as it is today with 11.7M average shares across the five names), it typically signals institutional conviction. Expect 60–70% of today's pre-market direction to carry into the regular session.

Which of these stocks is the best buy today?

That's not an investment recommendation—it depends on your risk tolerance and holding period. NVDA has the strongest analyst consensus (28 Buy ratings), but valuations are elevated at 45x forward earnings. MRNA has the biggest catalyst upside but highest risk due to biotech volatility. Learn how to evaluate valuations before making any decision.

What should I watch when the market opens at 9:30 a.m. ET?

Watch the first 15 minutes of trading (9:30–9:45 a.m.). This is when the biggest volume comes in, and it reveals whether institutional money is continuing to buy or selling into strength. If NVDA opens, holds its $142+ level, and pushes toward $145 in the first 30 minutes, expect a continued rally. If it fades below $140, it signals profit-taking and suggests the pre-market move was overdone.

How does today's pre-market action impact my portfolio?

If you own any of these five names, your positions are already pricing in the news. At the open, orders will fill at market-clearing prices—some higher than pre-market, some lower, depending on buy/sell pressure. Do not panic-sell or panic-buy at the open. Wait for the first 30 minutes of trading to settle before making moves. Follow market news for real-time updates.

Bottom Line: Watch the 9:30 a.m. Open Closely

Pre-market trading on August 26, 2026 is setting up to be volatile across multiple sectors—semiconductors (NVDA, INTC), pharma (LLY, REGN), and biotech (MRNA). The catalysts are real, but the moves are substantial. NVDA's 4.2% pre-market jump is significant; LLY's 5.8% decline is even more so, given the company's track record. MRNA's 6.9% surge on RSV data could be a turning point after a brutal 2025–2026.

The key is not to chase or panic at the open. Let the first 30 minutes settle, watch for volume confirmation, and check key support and resistance levels. If NVDA holds $140, LLY holds $680, MRNA breaks above $135, INTC stabilizes above $33, and REGN crosses $895, today could be a significant inflection point for the market.